Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab.

Arthritis Rheumatol · 2016 · PMC6099512 · PMID 27111089

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

marginally significantP = 0.05actually significant

Furthermore, a significant association between a European League Against Rheumatism–defined good response (18) at week 16 and change in the DAS28‐CRP over the first month of the study ( P = 0.02) was observed, whereas the association with change in MBDA score over this time period was marginally significant ( P = 0.05).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.